ATH (ASX) PBT434 inhibits alpha- synuclein in the brain.

Originally posted by pivalde: ↑

skint, this is an important statement by ATH and looks to be based on the Finkelstein paper and the MSA mouse study but not to phase 1 study (???).
The other day we got this report (below) how CSF alpha-synuclein is not so good in monitoring the progress in PD. It is not a free paper so I made my conclusions only by the abstract. IMO the paper does not contradict the statement by ATH but I think that it is worth posting. Brain alpha-synuclein is important, not CSF alpha-synuclein.

Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27806. [Epub ahead of print]
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Mollenhauer B¹, Caspell-Garcia CJ², Coffey CS², Taylor P³, Singleton A⁴, Shaw LM⁵, Trojanowski JQ^6,⁷, Frasier M⁸, Simuni T⁹, Iranzo A¹⁰, Oertel W¹¹, Siderowf A^7,¹², Weintraub D¹², Seibyl J¹³, Toga AW¹⁴, Tanner CM¹⁵, Kieburtz K¹⁶, Chahine LM¹⁷, Marek K¹³, Galasko D¹⁸; PPMI study.
Author information

Abstract
BACKGROUND:
Aggregation of α-synuclein is central to the pathophysiology of PD. Biomarkers related to α-synuclein may be informative for PD diagnosis/progression.
OBJECTIVES:
To analyze α-synuclein in CSF in drug-naïve PD, healthy controls, and prodromal PD in the Parkinson's Progression Markers Initiative.
METHODS:
Over up to 36-month follow-up, CSF total α-synuclein and its association with MDS-UPDRS motor scores, cognitive assessments, and dopamine transporter imaging were assessed.
RESULTS:
The inception cohort included PD (n = 376; age [mean {standard deviation} years]: 61.7 [9.62]), healthy controls (n = 173; age, 60.9 [11.3]), hyposmics (n = 16; age, 68.3 [6.15]), and idiopathic rapid eye movement sleep behavior disorder (n = 32; age, 69.3 [4.83]). Baseline CSF α-synuclein was lower in manifest and prodromal PD versus healthy controls. Longitudinal α-synuclein decreased significantly in PD at 24 and 36 months, did not change in prodromal PD over 12 months, and trended toward an increase in healthy controls. The decrease in PD was not shown when CSF samples with high hemoglobin concentration were removed from the analysis. CSF α-synuclein changes did not correlate with longitudinal MDS-UPDRS motor scores or dopamine transporter scan.
CONCLUSIONS:
CSF α-synuclein decreases early in the disease, preceding motor PD. CSF α-synuclein does not correlate with progression and therefore does not reflect ongoing dopaminergic neurodegeneration. Decreased CSF α-synuclein may be an indirect index of changes in the balance between α-synuclein secretion, solubility, or aggregation in the brain, reflecting its overall turnover. Additional biomarkers more directly related to α-synuclein pathophysiology and disease progression and other markers to be identified by, for example, proteomics and metabolomics are needed. © 2019 International Parkinson and Movement Disorder Society.

Expand

Pivalde it is based on the human trial. Look at the last announcement on their site.

No.	Vol.	Price($)
101	87272775	0.4¢

No.

Vol.

Price($)

101

87272775

0.4¢

Price($)	Vol.	No.
0.5¢	24185511	15

Price($)

Vol.

No.

0.5¢

24185511

No.	Vol.	Price($)
1	100000	0.005
101	101879028	0.004
63	62217433	0.003
18	33166014	0.002
16	108320102	0.001

No.

Vol.

Price($)

100000

0.005

101

101879028

0.004

62217433

0.003

33166014

0.002

108320102

0.001

Price($)	Vol.	No.
0.004	85006	2
0.005	24179262	14
0.006	22637365	20
0.007	26724705	23
0.008	28175438	30

Price($)

Vol.

No.

0.004

85006

0.005

24179262

0.006

22637365

0.007

26724705

0.008

28175438

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $21.28M

Open	High	Low	Value	Volume
0.4¢	0.5¢	0.4¢	$71.15K	17.43M

PBT434 inhibits alpha- synuclein in the brain., page-3

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Opyl forms JV with UK and US consortium to bring products to the world

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Drilling at Lady Ilse suggests gold-copper porphyry, grows footprint for Magmatic

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

PBT434 inhibits alpha- synuclein in the brain., page-3

Top Stories

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Opyl forms JV with UK and US consortium to bring products to the world

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Drilling at Lady Ilse suggests gold-copper porphyry, grows footprint for Magmatic

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News